natgillin/translations-raw huggingface dataset:
a head portion attached to the first end of the shaft portion, wherein the head portion is configured to rest on the exterior of the punctum; and 
(b) glavu, spojenu na prvi kraj trupa, gdje je glava tako oblikovana da se osloni o vanjštinu punktuma; i
Oxycodone HC1, lactose, and povidone are placed into a fluid bed granulator/dryer (FBD) bowl, and the suspension sprayed onto the powder in the fluid bed. 
2. < Oksikodon HCI, laktoza, i povidon su postavljeni u fluidiziranom sloju u posudu granulatora/sušilice (FBD), te je suspenzija raspršena u prah u fluidiziranom sloju.
Isomer D, which is believed to have either the 2 R,3 S,11b R or 2 S,3 R,11b S configuration (the absolute stereochemistry was not determined), was characterized by 1H-NMR, 13C-NMR, IR, mass spectrometry, chiral HPLC and ORD. 
Izomer D, za kojeg se smatra da ima ili 2R,3S,11bR ili 25,3R,11bS konfiguraciju (apsolutna stereokemija nije određena) je okarakteriziran pomoću!H-NMR,!*C-NMR, IR, masence spektromctrije, hiralnc HPLC i ORD.
Soft Randomization of the Hypervariable Regions:— 
Broj objave europskog patenta:
The antibacterial periodontal composition may further comprise at least one chelating agent. The chelating agent may be chosen from ethylenediaminetetraacetic acid (EDTA) and ethylene glycol tetraacetic acid (EGTA). 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-14, naznačena time što navedeni pripravak dodatno sadrži najmanje jedno kelirajuće sredstvo, koje se bira između etilendiamintetraoctene kiseline (EDTA) i etilen-glikol- tetraoctene kiseline (EGTA).
Preferably the free end of the dispensing tube is provided with a dispensing valve as well. 
Ponajprije, slobodan kraj cijevi za točenje ima također i ventil za točenje.
A trifluoroacetyl product produced by the process of any one of claims 1-11. 
Smjesa prema patentnom zahtjevu 27, naznačena time, da je boja smjese manja od 500 APHA.
A method according to claim 14 or claim 15 wherein the GPR119 agonist has an EC50 of less than 100 nM. 
Uporaba u skladu sa zahtjevom 37, naznačena time, da GPR119 agonist ima EC50 manji od 10 uM.
Use of a compound according to claim 1, a salt thereof or a hydrate of the foregoing, for the preparation of a medicament for inhibiting a hepatocyte growth factor receptor. 
Uporaba spoja prema zahtjevu 1, njegove soli ili hidrata, naznačena time da je za pripremu lijeka za inhibiciju receptora hepatocitnog faktora rasta,
Use according to any of the preceding articles, wherein the one or more oligomers of lactic acid is present in an oligomeric product having an average weight molecular weight of from about 300 to about 2,000. 
Jedan ili više oligomera mliječne kiseline za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je jedan ili više oligomera mliječne kiseline prisutan u oligomerskom proizvodu koji ima prosječnu masu molekularne mase od oko 300 do oko 2,000.
The third component: 1%-15%. 
Treća komponenta: 1%-15%.
That is, the bullet-shape container may be inverted so that the container rests on the ridges, and the cap is readily accessible. 
To znači, posuda oblika nalik metku se može okrenuti tako da posuda stoji na izbočenjima, i poklopac je lako dostupan.
The inner part of the packaging may be provided with a locking part such that the first and second side may be locked together. 
Unutarnji dio pakiranja može biti snabdjeven s takvim dijelom za blokiranje, tako da se prva i druga strana mogu zajedno blokirati.
demounting the brackets (60) in the tunnel element (14) from the outer propeller ring (41) of the at least one thruster unit (12); 
demontiranje držača (60) sa elementa tunela (14) sa vanjskog propelerskog prstena (41) barem jedne potisne jedinice (12);
a solution of Metformin hydrochloride salt is passed through an ion-exchange column in order to produce free Metformin, 
otopina soli metforminklorida prolazi kroz ionsko-izmjenjivačku kolonu radi dobivanja slobodnog metformina,
A wall 208 can separate and essentially seal off compressor 50 from pump 40.. 
Zid 208 može razdvojiti, u biti brtveno, kompresor 50 od pumpe 40.
The preparation according to claim 7, characterised by that said other polysaccharide is sulfoethyl-B-1,3-D-glucan having the molecular weight within the range of 1 000 to 1 500 000 g/mol and the substitution degree within the range of 0.05 to 3 expressed as the total amount of sulfoethyl groups to the total amount of monosaccharide units, and being in its free form or in the form of a pharmacologically suitable salt which is a sodium, potassium, lithium, calcium, magnesium, zinc, cobalt, manganese salt or another salt or a mixture thereof. 
Pripravak prema zahtjevu 7, naznačen time da je navedeni drugi polisaharid sulfoetil-B-1,3-D-glukan koji ima molekularnu težinu u rasponu od 1 000 do 1 500 000 g/mol i stupanj supstitucije u rasponu od 0.05 do 3 izraženo kao ukupna količina sulfoetilnih skupina prema ukupnoj količini monosaharidnih jedinica, te je u slobodnom obliku ili u obliku farmakološki pogodne soli koja je natrijeva, kalijeva, litijeva, kalcijeva, magnezijeva, cinkova, kobaltova, sol mangana ili druga sol ili njihova smjesa.
A method as claimed in claim 23, the method further comprising securing the flexible member relative to the support so that the flexible object is supported in the deployed position. 
105; 205) u odnosu na izduljeni oslonac (3; 103; 203) tako da se savitljivi predmet (7) podržava u uporabljivom položaju.
The solid oral extended release pharmaceutical dosage form of claim 1 or 2, wherein the density of the extended release matrix formulation is equal to or less than about 1.20 g/cm3, preferably equal to or less than about 1.19 g/cm3. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da je gustoća formulacije matrice sa produljenim otpuštanjem jednaka ili manja od oko 1.20 g/em poželjno jednaka ili manja od oko 1.19 g/em'.
A dose counter as claimed in claim 6, wherein the resilient bias is provided by at least one of: a leaf spring separate from the lever, a leaf spring integrally formed with the lever, a compression spring and/or a torsion spring. 
Brojač doze u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je barem jedna osovina pobuđivača (120) i s time povezana poluga (122) gipko otklonjena u odnosu na početnu poziciju, osovina pobuđivača (120) i povezana poluga (122) mogu se pomaknuti prema gipkom otklonu zbog pobuđivanja brojača doze.
Use according to claim 19, wherein the non-malignant disease is selected from the group comprising arthropathies and osteopathological conditions such as rheumatoid arthritis, osteoarthritis, gout, polyarthritis, and psoriatic arthritis, systemic lupus erythematosus, smooth muscle cell proliferation including vascular proliferative disorders, atherosclerosis and restenosis, inflammatory conditions and dermal conditions such as ulcerative colitis, Crohn's disease, allergic rhinitis, allergic dermatitis, cystic fibrosis, chronic bronchitis and asthma, endometriosis, uterine fibroids, endometrial hyperplasia and benign prostate hyperplasia, cardiac dysfunction, immunosuppressive conditions like HIV infections, neuropathological disorders like Parkinson disease, Alzheimer disease or polyglutamine related disorders, pathological conditions amenable to treatment by potentiating of endogenous gene expression as well as enhancing transgene expression in gene therapy. 
Upotreba u skladu s patentnim zahtjevom 19, naznačena time što se nezloćudnu bolest bira iz skupine koju čine artropatije 1 osteopatološka stanja, poput reumatoidnog artritisa, osteoartritisa, gihta, poliartritisa 1 psorijatičnog artritisa, sistemni eritematozni lupus, proliferacija stanica glatkih mišića, uključujući vaskularne proliferativne poremećaje, ateroskleroza i restenoza, upalna stanja i dermalna stanja, poput ulceroznog kolitisa, Crohnove bolesti, alergijskog rinitisa, alergijskog dermatitisa, cistične fibroze, kroničnog bronhitisa i astme, endometrioza, fibroidi u maternici, hiperplazija endometrija i dobroćudna hiperplazija prostate, disfunkcija srca, imunosupresivna stanja poput infekcija HIV-om, neuropatološki poremećaji, poput Parkinsonove bolesti, Alzheimerove bolesti ili poliglutaminski povezani poremećaji, patološka stanja koja se može liječiti potenciranjem ekspresije endogenog gena, kao i pojačavanjem ekspresije transgena kod genske terapije.
R2b, R3a, R3b and R15 are respectively and independently hydrogen, cyano, halogen, C1-4alkyl or C4-6cycloalkyl, said C1-4alkyl and C4-6cycloalkyl can optionally be substituted by 1, 2, 3 or 4 substituents independently selected from the group consisting of: halogen, cyano and carboxyl; 
b, R3a i R3b su respektivno i nezavisno vodik, cijano, halogen, C1-4alkil ili C4-6cikloalkil, spomenuti C1-4alkil i C4-6cikloalkil mogu izborno biti supstituirani s 1, 2, 3 ili 4 supstituenta nezavisno odabranih iz skupine koja se sastoji od: halogena, cijano i karboksila;
The use according to any one of claims 18 to 31, wherein the pathological conditions where oxidative stress plays an important role in their pathogenesis are selected from allergies, stroke, Alzheimer's disease, and ischemic cardiovascular diseases. 
Upotreba prema bilo kojem zahtjevu 18 do 31, naznačena time, da su patološka stanja u čijoj patogenezi ima važnu ulogu oksidativan stres odabrana iz skupine koju čine alergije, udar kapi, Alzheimerova bolest 1 ishemijske kardiovaskularne bolesti.
A salt according to claim 6, wherein the amine is selected from the group consisting of deanol, diethanolamine, diethylethanolamine, ethanolamine, meglumine, 2-morpholine ethanol, 1-(2-hydroxyethyl)-pyrrolidine, triethanolamine and tromethamine; preferably the amine is selected from the group consisting of diethanolamine, meglumine, triethanolamine and tromethamine; more preferably from the group consisting of meglumine and tromethamine. 
Sol prema zahtjevu 6, naznačena time, što je amin odabran iz grupe koju čine deanol, dietanolamin, dietiletanolamin, etanolamin, meglumin, 2-morfolin etanol, 1-(2-hidroksietil)-pirolidin, trietanolamin i trometamin; poželjno,amin odabran iz grupe koju čine dietanolamin, meglumin, trietanolamin i trometamin; najpoželjnije, amin odabran iz grupe koju čine meglumin i trometamin.
In some embodiments alkyl contains 1 to 13 carbons, some embodiments contain 1 to 2 carbons, some embodiments contain I carbon. 
U nekim oblicima alkil sadrži 1 do 3 ugljika, neki oblici sadrže 1 do 2 gljika, neki oblici sadrže 1 ugljik.
the viscosity is 10-50 Pas measured with a shear rate of 10-50 s-1, the viscosity is 0.4-1.5 Pas measured with a shear rate of 200-210 s-1, and 0.1-0.4 Pas measured with a shear rate of 600-610 s-1. 
viskozitet je 10-50 Pas izmjerena stopom smicanja od 10-50 s", viskozitet je 0.4-1.5 Pas izmjerena stopom smicanja od 200-210 s", i 0.1-0.4 Pas izmjerena stopom smicanja od 600-610 s".
During such a process the temperature of the elastomer material adjacent the puncture site may be measured using a suitable temperature sensor, or the equipment used to perform the process may be pre-calibrated to achieve the suitable temperature. 
Za vrijeme takvog postupka temperatura elastomernog materijala, koja se nalazi uz mjesto proboda, može se mjeriti tako da se koristi prikladan temperaturni senzor, ili se može oprema koja se koristi za provođenje postupka unaprijed kalibrirati tako da se postigne prikladna temperatura.
The plates were analysed according to manufacturers instruction (Alpha screen, Perkin Elmer (Pachard Biosciense)). 
Ploče se analiziraju prema uputama proizvođača (Alpha screen, perkin Elmer (Pachard Biosciense)).
Although a cylindrical section 50 seats flush against cup 12 above shoulder 32, it should be understood that the cylindrical section 50 is not bonded to the cup body at locations other than the ring of discrete spot bonds 53. Also, the spot bonds or spot welds 53 are separated from each other by bonding-free parts along the contact path 3. 
Iako cilindrična sekcija 50 naliježe na čašu 12 iznad izbočenja 32 tako da je s njim izravnana, jasno je da sekcija 50 nije spojena na tijelo čaše iznad prstena točaka spajanja 53 i da su odgovarajuća točkasta spajanja ili točkasta zavarena mjesta 53 odvojena jedno od drugoga s dijelovima bez spojnih mjesta odgovarajuće staze za kontakte 3.
An apparatus according to claim 19, further comprising further air supply means positioned to direct a further air flow at the fibres and binder, when they are suspended in the primary air flow. 
Uređaj sukladno patentnom zahtjevu 19, nadalje obuhvaća dodatni uređaj za dovod zraka postavljen usmjeriti dalji protok zraka na vlakna i vezivno sredstvo, kada lebde u primarnom protoku zraka.
A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1, wherein: 
Derivat pirimidona, ili njegova sol, ili njegov solvat ili njegov hidrat, u skladu s patentnim zahtjevom 1, naznačen time što:
The amount indicates that ca 10% of the FAME in the formulation is unreacted. Example 3 
Količina pokazuje da u formulaciji nije izreagiralo pribl. 10% FAME. Primjer 2
Start the stirrer on slow speed and add 2.1 kg of Orange Oil BP and 0.5 kg of Lemon Oil Ph.Eur. 
Uključiti mješalicu na sporu brzinu i dodati 2.1 kg narančinog ulja BP 1 0.5 kg limunovog ulja Ph. Eur.
The solid dosage form of claim 10, wherein the solid dosage form takes the form of a bilayer tablet having the flurbiprofen or pharmaceutically acceptable salts thereof in one layer and a a-2 adrenergic receptor agonist or a gamma-aminobutiric acid receptor agonist in another layer. 
Čvrsti dozni oblik prema zahtjevu 10, naznačen time što je rečeni čvrsti dozni oblik formuliran kao dvoslojna tableta koja sadrži flurbiprofen ili njegovu farmaceutski prihvatljivu sol u jednom sloju, a agonist a-2 adrenergičkog receptora, ili agonist gama-aminobutanske kiseline u drugom sloju.
determining with the processor mechanism evidence of at least a third user mark in the detected third user marking cell based at least in part upon a degree of brightness similarity between: (a) at least a portion of the electronic image surrounding the indicium bounding the third user marking cell; and (b) at least a portion of the electronic image included inside the indicium bounding the third user marking cell. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što dodatno uključuje: određivanje procesorskim mehanizmom dokaza o u najmanju ruku trećoj korisničkoj oznaci u detektiranoj trećoj ćeliji za korisničku oznaku na temelju u najmanju ruku dijelom stupnja sličnosti svjetline između: (a) u najmanju ruku dijela elektronske slike koji okružuje bilješku koja omeđuje treću ćeliju za korisničku oznaku; 1 (b) u najmanju ruku dijela elektronske slike koji se nalazi unutar bilješke koja omeđuje treću ćeliju za korisničku oznaku.
is phenyl or an optionally substituted 5-6 membered heterocyclic ring; 
Ri, je fenil ili po izboru supstituirani petero do šesteročlani heterociklički prsten;
The antibody or fragment thereof of claim 1, wherein the antibody or fragment thereof comprises: (a) a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO: 58 or SEQ ID NO: 59; and 
Protutijelo ili njegov fragment sukladno patentnom zahtjevu 1 naznačeno time da, to protutijelo ili njegov fragment sadrži: (a) sekvencu promjenjive regije teškog lanca koja sadrži aminokiselinsku sekvencu SEK ID BR: 58 ili SEK ID BR: 59; 1
The composition for use of claim 1, further comprising at least one additional compound selected from the group consisting of Sulfisoxazole, Methimazole, Prilocaine, Dyphylline, Quinacrine, Carbenoxolone, Aminocaproic acid, Cabergoline, Diethylcarbamazine, Cinacalcet, Cinnarizine, Eplerenone, Fenoldopam, Leflunomide, Levosimendan, Sulodexide, Terbinafine, Zonisamide, Etomidate, Phenformin, Trimetazidine, Mexiletine, Ifenprodil, Moxifloxacin, Bromocriptine or Torasemide, or pharmaceutically acceptable salts thereof. 
Smjesa za uporabu prema zahtjevu 1, dalje sadrži barem jedan dodatni spoj izabran iz grupe koja obuhvaća sulfizoksazol, metimazol, prilokain, difiln, kvinakrin, karbenoksolon, aminokaproičnu kiselinu, kabergolin, dietilkarbamazin, sinakalcet, cinarizin, eplerenon, fenoldopam, leflunomid, levosimendan, sulodeksid, terbinafin, zonisamid, etomidat, fenformin, trimetazidin, meksiletin, ifenprodil, moksifloksacin, bromokriptin ili torasemid, ili njihove farmaceutski prihvatljive soli.
Clearly, changes may be made to the rotary mixing member 1 as described and illustrated herein without, however, departing from the scope of the present invention. 
Jasno je, da se na rotacionom članku za miješanje 1, kako je ovdje opisan i ilustriran, mogu izvršiti izmjene bez odstupanja od opsega predmetnog izuma kako je definiran u pridodanim patentnim zahtjevima.
The pharmaceutical composition of claim 9, wherein the additional therapeutic agent is selected from an anticancer compound, an analgesic, an antiemetic, an antidepressant, and an anti-inflammatory agent. 
Farmaceutski sastav prema zahtjevu 6, naznačen time, da je dodatno terapeutsko sredstvo odabrano između protutumorskog sredstva, analgetika, antiemetika, antidepresiva i protuuplanog sredstva.
The method of any of Claims 1-5, wherein said at least one protein of interest is a transcription factor, and wherein said plurality of days is a sufficient number of days to reprogram said cell, including wherein: the method is performed without the use any exogenous protein, siRNA, or small molecule agent that inhibits or reduces the activation, induction or the expression of one or more proteins in an innate immune response pathway. 
iv) navedena ssRNA ili mRNA sadrži najmanje jedan modificirani ribonukleozid, izabran iz skupine koja sadrži pseudouridin, 1-metilpseudouridin, 5-metilcitidin, 5-metiluridin, 2'-O-metiluridin i 2-tiouridin umjesto najmanje dio odgovarajućeg nemodificiranog kanonskog ribonukleozida, koji smanjuje indukciju ili aktivaciju RNA senzora ili urođenog puta imunog odgovora u stanici;
The compound for use of any one of claims 6-7, wherein the pharmaceutically acceptable derivative is 
Tvar iz patentnog zahtjeva 4, pri čemu je farmaceutski prihvatljivi derivat
The use of a combination of any one of claims 1-7 for the manufacture of a medicament for the treatment or prevention of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage. 
Primjena spoja prema bilo kojem od zahtjeva 1 do 9, ili njegove farmaceutski prihvatljive soli, stereoizomera ili tautomera, naznačena time što služi za proizvodnju lijeka za liječenje ili prevenciju tumora, upalnih bolesti, Teperfuzionih povreda, iskemijskih stanja, moždanog udara, bubrežne insuficijencije, kardiovaskularnih bolesti, vaskularnih bolesti različitih od kardiovaskularnih bolesti, dijabetesa, neurodegenerativnih bolesti, retrovirusnih infekcija, oštećenja mrežnice ili starenja kože i oštećenja kože izazvanih UV-zračenjem.
An antagonist of M3 muscarinic receptors for use according to claim 16 wherein the patient is suffering from a pre-existing heart condition or condition that would be aggravated by tachycardia A B2 agonist as defined in claim 1 or 3, for simultaneous, concurrent, separate or sequential use in combination with an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the treatment of a respiratory disease as defined in claim 7 or 8. 
Antagonist M3 muskarinskih receptora, za uporabu u skladu sa zahtjevom 16, naznačen time, da pacijent pati od postojećeg stanje srca ili stanja koje će biti pogoršano tahikardijom B2 agonist kako je definirano u patentnom zahtjevu 1 ili 3, naznačen time, da je namijenjen za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u kombinaciji s antagonistom M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 1li 2 za liječenje dišnih bolesti kao što je definirano u zahtjevu 7 ili 8.
The method of claim 15, wherein the cancer is one or more of cancer of the buccal cavity or pharynx, cancer of the digestive tract, cancer of the colon, rectum, or anus, cancer of the respiratory tract, breast cancer, cancer of the cervix uteri, vagina, or vulva, cancer of the uterine corpus or ovary, cancer of the male genital tract, cancer of the urinary tract, bone or soft tissue cancer, Kaposi sarcoma, melanoma of the skin, ocular melanoma, non-melanoma eye cancer, cancer of the brain and central nervous system, cancer of the thyroid and other endocrine glands, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, myeloma, renal cancer, colorectal cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, gastric cancer, GIST or glioblastoma. 
Farmaceutski sastav za uporabu prema zahtjevu 12, pri čemu je karcinom karcinom usne šupljine 1 ždrijela, karcinom probavnog trakta, karcinom debelog crijeva, rektuma i anusa, karcinom respiratornog trakta, karcinom dojke, karcinom grlića maternice, vagine i vulve, karcinom tijela maternice 1 jajnika, karcinom muškog genitalnog trakta, karcinom urinarnog trakta, karcinom kostiju i mekog tkiva, Kaposijev sarkom, melanom kože, melanom oka, nemelanomski karcinom oka, karcinom mozga i središnjeg živčanog sustava, karcinom žlijezde štitnjače i drugih endokrinih žlijezda, Hodgkinov limfom, ne-Hodgkinov limfom, ili mijelom kao što su karcinom bubrega, kolorektalni karcinom, karcinom pluća, karcinom dojke, karcinom gušterače, karcinom prostate, karcinom želuca, gastrointestinalni stromalni tumor (GIST) ili glioblastom.
A composition comprising at least one isolated anti IL-6 antibody according to any of claims 1-3 and at least one pharmaceutically acceptable carrier or diluent, optionally further comprising at least one compound or polypeptide selected from a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist. 
Sastav koji sadrži najmanje jedno izolirano IL-6 antitijelo prema bilo kojem od patentnih zahtjeva od 1 do 4 i najmanje jedan farmaceutski prihvatljiv nosač ili razrjeđivač. Preparat prema patentnom zahtjevu 10 koji nadalje sadrži najmanje jedan spoj ili polipeptid izabran iz grupe koju čine detektabilna oznaka ili reporter, antagonist TNF, anti-infektivni lijek, lijek za kardiovaskularni (KV) sustav, lijek za središnji živčani sustav (CNS), lijek za autonomni živčani sustav (ANS), lijek za respiratorni trakt, lijek za gastrointestinalni (GI) trakt, hormonski lijek, lijek za održavanje ravnoteže fluida ili elektrolita, hematološki lijek, antineoplastik, imunomodulatorni lijek, oftamološki, otički ili nazalni lijek, topički lijek, nutriticionistički lijek, citokin ili antagonist citokina.